Health Care [ 8/12 ] | Pharmaceuticals [ 40/76 ]
NYSE MKT | Common Stock
NovaBay Pharmaceuticals, Inc. develops and sells eyecare and wound care products in the United States and internationally.
It offers Avenova Spray, a solution for removing foreign materials, including microorganisms and debris from skin around the eye, such as the eyelid; Avenova Eye Health Support antioxidant-rich oral supplements; Avenova Lubricating Eye Drops for instant relief; NovaWipes by Avenova; Avenova WarmEye Compress to soothe the eyes; and the i-Chek by Avenova to monitor physical eyelid health.
The company also provides wound care products, which are used for cleansing and irrigation as part of surgical procedures, as well as treating wounds, burns, ulcers, and other injuries under the NeutroPhase and PhaseOne brands.
It sells its products through the company's web stores, third-party online retailers and distribution partners.
The company was formerly known as NovaCal Pharmaceuticals, Inc. and changed its name to NovaBay Pharmaceuticals, Inc. in February 2007.
NovaBay Pharmaceuticals, Inc. was incorporated in 2000 and is headquartered in Emeryville, California.
| Reported date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| Aug 13, 24 | -1.37 Decreased by -114.06% | -1.23 Decreased by -11.38% |
| May 9, 24 | -0.15 Increased by +82.35% | -0.15 |
| Mar 26, 24 | -1.33 Decreased by -70.51% | -0.30 Decreased by -343.33% |
| Nov 9, 23 | -0.37 Increased by +89.43% | -0.40 Increased by +7.50% |
| Aug 10, 23 | -0.64 Increased by +54.29% | -0.56 Decreased by -14.29% |
| May 11, 23 | -0.85 Increased by +51.43% | -0.91 Increased by +6.59% |
| Mar 30, 23 | -0.78 Decreased by -11.43% | -0.17 Decreased by -358.82% |
| Nov 14, 22 | -3.50 Decreased by -100.00% | -1.23 Decreased by -184.55% |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Jun 30, 24 | 2.40 M Decreased by -47.94% | -1.58 M Increased by +60.69% | Decreased by -66.04% Increased by +24.49% |
| Mar 31, 24 | 2.63 M Decreased by -15.78% | -3.21 M Decreased by -84.82% | Decreased by -122.16% Decreased by -119.45% |
| Dec 31, 23 | 3.73 M Increased by +2.31% | -4.11 M Increased by +49.94% | Decreased by -110.22% Increased by +51.07% |
| Sep 30, 23 | 3.25 M Decreased by -14.92% | -1.76 M Increased by +69.67% | Decreased by -53.98% Increased by +64.35% |
| Jun 30, 23 | 4.61 M Increased by +51.40% | -4.03 M Decreased by -87.10% | Decreased by -87.46% Decreased by -23.58% |
| Mar 31, 23 | 3.12 M Increased by +18.83% | -1.74 M Decreased by -1.47 K% | Decreased by -55.67% Decreased by -1.22 K% |
| Dec 31, 22 | 3.64 M Increased by +37.94% | -8.21 M Decreased by -818.92% | Decreased by -225.25% Decreased by -566.18% |
| Sep 30, 22 | 3.83 M Increased by +107.93% | -5.79 M Decreased by -153.08% | Decreased by -151.41% Decreased by -21.71% |